Share on StockTwits

Alkermes Plc (NASDAQ:ALKS) is scheduled to be issuing its quarterly earnings data on Wednesday, April 30th. Investors that are interested in participating in the company’s conference call can do so using this link.

Alkermes Plc (NASDAQ:ALKS) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.27 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.20 by $0.07. The company had revenue of $154.50 million for the quarter, compared to the consensus estimate of $142.93 million. During the same quarter last year, the company posted $0.34 earnings per share. Alkermes Plc’s revenue was up 13.6% compared to the same quarter last year. On average, analysts expect Alkermes Plc to post $0.50 EPS for the current fiscal year and $0.76 EPS for the next fiscal year.

Shares of Alkermes Plc (NASDAQ:ALKS) opened at 45.45 on Tuesday. Alkermes Plc has a 52 week low of $26.47 and a 52 week high of $54.25. The stock’s 50-day moving average is $44.66 and its 200-day moving average is $43.01. The company has a market cap of $6.553 billion and a price-to-earnings ratio of 279.06.

A number of analysts have recently weighed in on ALKS shares. Analysts at Zacks downgraded shares of Alkermes Plc from an “outperform” rating to a “neutral” rating in a research note on Wednesday, April 16th. They now have a $45.00 price target on the stock. On the ratings front, analysts at Mizuho upgraded shares of Alkermes Plc from a “neutral” rating to a “buy” rating in a research note on Thursday, April 10th. They now have a $61.00 price target on the stock, up previously from $56.00. Finally, analysts at MKM Partners raised their price target on shares of Alkermes Plc from $32.00 to $35.00 in a research note on Wednesday, April 9th. They now have a “sell” rating on the stock. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Alkermes Plc currently has an average rating of “Hold” and an average target price of $46.44.

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.